Increasing incentives to contribute to R&D and auditing through stock options
First written in FY2020-Q2. 21 of 22 entries say "Advanced", first in FY2020-Q3. Latest entry: FY2026.
- FY2026AdvancedAnnual report
「At a meeting of the Board of Directors held on 9 September 2026, the Company resolved to issue stock acquisition rights as stock options to its directors and employees for the purpose of enhancing their motivation and morale to contribute to the progress of the Company's research and development and thereby increasing corporate value. The rights were issued on 10 September 2026.」
To encourage contributions to research and development and enhance corporate value, additional issues of the 19th and 20th series of stock acquisition rights were made, including rights covering 300,000 shares for 4 directors and 498,900 shares for 47 executive officers and employees. - FY2025AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 September 2025, the Company resolved to issue stock acquisition rights as stock options to its directors, employees, dispatched employees and outside collaborators, with the aim of enhancing motivation and morale to contribute to the progress of the Company's research and development and thereby contributing to the enhancement of corporate value. The rights were issued on 11 September 2025 and 26 September 2025.」
After the filing date, additional stock options were issued to directors, employees, dispatched employees and outside collaborators, continuing and expanding the incentive programme. - FY2025-H1AdvancedAnnual report
「Name: Series 15 Stock Acquisition Rights (d) Resolution date: 25 July 2024 Category and number of grantees (people): Company dispatched employees, 3 Outside collaborator, 1 Number of stock acquisition rights (units)*: 480 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 48,000 (Note 1) Exercise period for the stock acquisition rights*: From 10 August 2026 To 9 August 2033」
The Company issued Series 15 Stock Acquisition Rights to 3 dispatched employees and 1 outside collaborator, with 48,000 shares of common stock underlying the rights, and set an exercise period from August 2026 to August 2033. - FY2024AdvancedAnnual report
「At a meeting of the Board of Directors held on 25 July 2024, the Company resolved to issue stock acquisition rights as stock options to its dispatched employees and outside collaborators, as approved at the annual general meeting of shareholders held on 25 October 2023, with the aim of enhancing motivation and morale to contribute to the progress of the Company's research and development and thereby contributing to the enhancement of corporate value. The rights were issued on 9 August 2024.」
The issue of stock acquisition rights to dispatched employees and outside collaborators was further specified, with the aim of increasing motivation to contribute to research and development and enhancing corporate value. - FY2024-Q3AdvancedAnnual report
「Stock acquisition rights issued during the third quarter of the current fiscal year are as follows. Name: Series 15 Stock Acquisition Rights (b) Resolution date: 29 February 2024 Category and number of grantees (people): Company outside collaborators, 3 Number of stock acquisition rights (units)*: 750 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 75,000 (Note 1) Exercise period for the stock acquisition rights*: From 1 March 2026 to 28 February 2033」
The Company issued Series 15 Stock Acquisition Rights to 3 outside collaborators, with 75,000 shares of common stock underlying the rights, and set an exercise period from March 2026 to February 2033. - FY2024-Q2AdvancedAnnual report
「Name: Series 15 Stock Acquisition Rights (a) Resolution date: 13 December 2023 Category and number of grantees (people): Company outside collaborator, 1 Number of stock acquisition rights (units)*: 300 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 30,000 (Note 1)」
During the second quarter, the Company issued Series 15 Stock Acquisition Rights to 1 outside collaborator, with 30,000 shares of common stock underlying the rights, further specifying the incentive programme aimed at increasing motivation to contribute to research and development and other activities. - FY2024-Q1AdvancedAnnual report
「Stock acquisition rights issued during the first quarter of the current fiscal year are as follows. Name: Series 13 Stock Acquisition Rights (c) Resolution date: 13 September 2023 Category and number of grantees (people): Company executive officers, 1; Company employees, 32 Number of stock acquisition rights (units)*: 3,083 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 308,300 (Note 1)」
During the first quarter, the Company issued Series 13 Stock Acquisition Rights equivalent to 308,300 shares to executive officers and employees. The issue of stock acquisition rights to outside collaborators and directors was also disclosed, indicating that the incentive programme was continuing to take concrete form. - FY2023AdvancedAnnual report
「Series 13 Stock Acquisition Rights (c) Category and number of grantees (people): Company executive officers, 1; Company employees, 32 Number of stock acquisition rights (units)*: 3,083 Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 308,300」
On 13 September 2023, after the filing date, Series 13 Stock Acquisition Rights equivalent to 308,300 shares were granted to executive officers and employees, and measures to grant stock acquisition rights to outside collaborators and directors were further specified. - FY2023-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 8 February 2023, the Company resolved to issue stock acquisition rights as stock options to its employees and dispatched employees, as approved at the annual general meeting of shareholders held on 26 October 2022, with the aim of enhancing motivation and morale to contribute to the progress of the Company's research and development and thereby contributing to the enhancement of corporate value.」
A resolution was passed to issue Series 13 Stock Acquisition Rights equivalent to 110,000 shares to 9 employees and 26,000 shares to 3 dispatched employees, continuing and expanding the stock option programme aimed at increasing motivation to contribute to research and development. - FY2022AdvancedAnnual report
「Resolution date: 18 August 2022 Category and number of grantees (people): Company executive officers, 2; Company employees, 1 Number of stock acquisition rights (units)*: 1,300 (Notes 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 130,000 (Notes 1 and 5)」
A resolution was recorded to grant Series 11 Stock Acquisition Rights equivalent to 130,000 shares to executive officers and employees on 18 August 2022, after the filing date, indicating that the incentive programme was continuing and expanding. - FY2022-Q3AdvancedAnnual report
「Resolution date: 14 April 2022 Category and number of grantees (people): Company employees, 33 Number of stock acquisition rights (units)*: 3,576 Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 357,600 (Note 1) Exercise period for the stock acquisition rights*: From 16 April 2024 to 14 April 2032」
Under Series 11 Stock Acquisition Rights, 3,576 stock acquisition rights equivalent to 357,600 shares of common stock were granted to 33 employees, with an exercise period from April 2024 to April 2032. - FY2021AdvancedAnnual report
「Number of stock acquisition rights (units): 13,050 Number of underlying shares (shares): 1,305,000」
Under Series 10 Stock Acquisition Rights (a), 13,050 stock acquisition rights equivalent to 1,305,000 shares were granted to directors, audit & supervisory board members, executive officers and employees. - FY2021-Q1AdvancedAnnual report
「Company executive officers: 2 Company employees: 4 Number of stock acquisition rights (units)*: 1,995 Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 199,500」
Under Series 9 Stock Acquisition Rights, 1,995 stock acquisition rights equivalent to 199,500 shares were granted to 2 executive officers and 4 employees, with additional rights issued to outside collaborators. - FY2020AdvancedAnnual report
「Based on a resolution of the Board of Directors dated 14 May 2020, 6,984 stock acquisition rights equivalent to 698,400 shares were granted to 4 directors, 1 audit & supervisory board member and 7 employees under Series 9 Stock Acquisition Rights (c).」
In addition to the existing stock option programme, 6,984 stock acquisition rights equivalent to 698,400 shares were granted to directors, audit & supervisory board members and employees in May 2020. - FY2020-Q3AdvancedAnnual report
「(1) Series 9 Stock Acquisition Rights (c) ③ Number of stock acquisition rights issued: 6,984 ⑤ Class and number of shares underlying the stock acquisition rights: 698,400 shares of common stock of the Company」
In addition to existing issues of stock acquisition rights, a resolution was recorded to issue 6,984 stock acquisition rights equivalent to 698,400 shares to directors, audit & supervisory board members and employees in May 2020. - FY2020-Q2First statedAnnual report
「The stock options will be issued free of charge in order to appropriately achieve the above objectives: to enhance motivation and morale to contribute to the progress of the Company's research and development, thereby contributing to the enhancement of corporate value, and to heighten the awareness of the Company's audit & supervisory board members regarding the rigorous conduct of audits.」
The policy and measures of issuing stock acquisition rights to directors, audit & supervisory board members, employees and outside collaborators, with the aim of encouraging contributions to research and development, enhancing corporate value and raising awareness of auditing, were described for the first time. The issue covered a total of 1,484,200 shares for 7 directors, 3 audit & supervisory board members, 8 employees and others, with the exercise period also specified.